Reference: GILA/ID/PE-053/FERM
Board seat: Independent Director, Non-Executive
Primary board location: Bengaluru with pilot and commercial plant visits
Meeting model: Eight boards, scientific risk reviews and financing gates
Mandate type: PE/VC-Backed Company Governance Mandate
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
A venture-backed biotechnology company producing specialty proteins and ingredients through engineered fermentation, moving from pilot batches to first commercial plant.
Capital raised is USD 70–100 million. Revenue is pre-scale and customer offtake depends on regulatory approvals, yield, consistency and unit economics at commercial volume.
The board problem and strategic reason for appointment
The board needs independence between scientific founders and financial investors at the point where technical risk becomes irreversible capex. Milestone language, IP freedom-to-operate, biosafety and offtake claims must withstand challenge.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
Contractual independent director; Chair of Technology/Investment Risk; voluntary Audit member.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Set technical-readiness gates for strain performance, downstream recovery, contamination and batch reproducibility; separate signed offtake, qualified interest and contingent volume; review IP ownership, inventor obligations and freedom-to-operate; govern commercial-plant capex, commissioning runway and alternate financing if yield ramp slips
- Clarify how statutory-board duties interact with reserved matters, investor consent rights, founder control, information rights and the path to exit; record where the independent director must arbitrate rather than align.
- Build a board pack that reconciles growth narrative with cash, unit economics, customer concentration, control maturity and downside runway under a delayed fundraise or exit.
Decision profile sought
Essential evidence
- Industrial biotech, fermentation, process scale-up, deep-tech investing or project-finance leader; board decision skill under technical uncertainty
Differentiators
- First-of-kind plant commissioning, regulatory novel-food/ingredient approval or failed scale-up experience; IP governance
GILA will assess growth-stage or buyout governance, fluency in shareholder-agreement mechanics, independence from both fund and founder, and experience when the plan did not work. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Fund, founder, university, licensor, EPC or prospective customer relationships; personal IP claims; advisory role in the technology.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects a board that can make difficult financing, founder and scaling decisions without confusing investor preference with company interest. For this particular seat, the evidence will be:
- Capital releases match verified technical gates; offtake claims are classified and auditable; IP, biosafety and downside runway have board-owned evidence
Commitment, protection and economics
- Expected load: 26–34 days annually during scale-up.
- Terms: Three-year initial term; fixed fee; equity considered only under explicit independence framework; biosafety/product and D&O cover.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.